Fig. 2From: Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart reviewACT score (a) and dose of glucocorticoids (mg/d) (b). ACT score (a) and dose of glucocorticoids (mg/d) (b) in patients with and without allergic rhinitis (AR) before and after omalizumab administration. *p < 0.05. **p < 0.01. ***p > 0.05. ACT, asthma control testBack to article page